View Older Stories View More Recent Stories

Jan 19, 2023 07:30AM Soligenix Invited to Present at the Virtual Investor Summit Event
Jan 15, 2023 04:00PM Soligenix On Track to Deliver Important Front-Line Treatment to US Market in 2024
Dec 23, 2022 04:01PM Soligenix Announces Distribution of Series D Preferred Stock to Holders of its Common Stock
Dec 20, 2022 07:30AM Soligenix Announces Publication Demonstrating Positive Correlates of Protection with RiVax® in Non-Human Primate Survival after Ricin Challenge
Dec 19, 2022 07:30AM Soligenix Initiates Phase 2 Clinical Trial of SGX302 (synthetic hypericin) for the Treatment of Mild-to-Moderate Psoriasis
Dec 15, 2022 07:31AM Soligenix, Inc. (SNGX) Submits NDA for HyBryte
Dec 15, 2022 07:30AM Soligenix Announces Submission of New Drug Application to the FDA for HyBryte™ in the Treatment of Cutaneous T-cell Lymphoma
Nov 15, 2022 07:31AM Soligenix, Inc. (SNGX) to Receive $1.2 M in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program
Nov 15, 2022 07:30AM Soligenix to Receive $1.2 M in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program
Nov 10, 2022 07:30AM Soligenix Announces Recent Accomplishments And Third Quarter 2022 Financial Results
Nov 7, 2022 09:30AM New to The Street Announces Five Corporate Interviews on Episode #404, Airing on the Fox Business Network, Tonight, Monday, November 7, 2022, at 10:30 PM PT
Oct 27, 2022 07:30AM Soligenix, Inc. (SNGX) Invited to Submit BARDA Contract Proposal for Development of Thermostabilized Subunit Vaccines for Sudan Ebola and Marburg Viruses
Oct 27, 2022 07:30AM Soligenix Invited to Submit BARDA Contract Proposal for Development of Thermostabilized Subunit Vaccines for Sudan Ebola and Marburg Viruses
Oct 25, 2022 07:30AM Soligenix Announces Formation of Psoriasis Medical Advisory Board
Oct 24, 2022 09:30AM New to The Street TV Announces its 399th Show, Featuring Five Corporate Interviews, Airing on the Fox Business Network, Tonight, Monday, October 24, 2022, at 10:30 PM PT
Oct 21, 2022 09:30AM New to The Street / Newsmax TV Announces its Nine Corporate Interviews for This Week's TV Broadcast, Episode #398, October 23, 2022, 10-11 AM ET
Oct 20, 2022 08:30AM Soligenix Announces Adjournment of Annual Meeting and Information for Reconvened Meeting
Oct 17, 2022 10:16AM UPDATE: New to The Street to Feature Soligenix Appearances on Its Syndicated Televised Outlets
Oct 17, 2022 08:30AM New to The Street to Feature Soligenix Appearances on Its Syndicated Televised Outlets
Sep 23, 2022 07:30AM Soligenix Announces Partial Adjournment of Annual Meeting and Information for Reconvened Annual Meeting
Sep 8, 2022 07:30AM Soligenix to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Sep 6, 2022 07:32AM Soligenix, Inc. (SNGX) Awarded $2.6 Million FDA Orphan Products Development Grant for Expanded Study of HyBryte
Sep 6, 2022 07:30AM U.S. Food and Drug Administration Awards $2.6 Million Orphan Products Development Grant for Expanded Study of HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma
Aug 16, 2022 07:00AM Presenting on the Emerging Growth Conference on August 17 Register Now
Aug 12, 2022 07:30AM Soligenix Announces Recent Accomplishments And Second Quarter 2022 Financial Results
Jul 27, 2022 07:31AM Soligenix, Inc. (SNGX) Announces FDA Agreement on Initial Pediatric Study Plan for HyBryte
Jul 27, 2022 07:30AM Soligenix Receives Agreement from FDA on Initial Pediatric Study Plan for HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma
Jul 25, 2022 07:31AM Soligenix, Inc. (SNGX) and SERB Pharmaceuticals Partner for Supply of Ricin Antigen
Jul 25, 2022 07:30AM Soligenix Announces Strategic Partnership with SERB Pharmaceuticals to Supply its Novel Ricin Antigen
Jul 20, 2022 11:18AM Soligenix (SNGX) Announces Publication of HyBryte Phase 3 FLASH Study for Treatment of Cutaneous T-Cell Lymphoma
Jul 20, 2022 11:17AM HyBryte™ Phase 3 FLASH Study for the Treatment of Cutaneous T-Cell Lymphoma Published in JAMA Dermatology
Jun 28, 2022 07:30AM Soligenix, Inc. (SNGX) Receives FDA IND Clearance for Phase 2 Clinical Trial of Synthetic Hypericin in the Treatment of Psoriasis
Jun 28, 2022 07:30AM Soligenix Receives FDA IND Clearance for Phase 2 Clinical Trial of Synthetic Hypericin in the Treatment of Psoriasis
Jun 23, 2022 07:32AM Soligenix, Inc. (SNGX) Reports Successful Protection using a Bivalent Thermostabilized Filovirus Vaccine
Jun 23, 2022 07:30AM Soligenix Announces Successful Protection using a Bivalent Thermostabilized Filovirus Vaccine
Jun 1, 2022 07:30AM Key Binding Characteristics of Dusquetide to Important Intracellular Protein Identified
May 23, 2022 07:30AM Soligenix Receives US Patent Allowance for its Thermostabilized Vaccine Platform
May 18, 2022 07:30AM Soligenix to Present at the H.C. Wainwright Global Investment Conference
May 13, 2022 07:30AM Soligenix Announces Recent Accomplishments And First Quarter 2022 Financial Results
Apr 19, 2022 07:30AM Soligenix (SNGX) Receives $1.4M in Non-Dilutive Government Funding
Apr 19, 2022 07:30AM Soligenix Receives $1.4M in Non-Dilutive Government Funding
Mar 29, 2022 07:30AM Soligenix Announces Recent Accomplishments And Year-End 2021 Financial Results
Mar 17, 2022 07:30AM Soligenix's (SNGX) CiVax Boosts Neutralizing Activity against SARS-CoV-2, including Delta and Omicron
Mar 17, 2022 07:30AM Soligenix COVID-19 Vaccine, CiVax™, Boosts Neutralizing Activity against SARS-CoV-2, including Delta and Omicron
Mar 2, 2022 07:30AM Soligenix to Present at the Q1 Virtual Investor Summit
Mar 1, 2022 03:04PM Soligenix, Inc. to Present at the Q1 Virtual Investor Summit
Feb 8, 2022 07:30AM Soligenix to Present at the 2022 BIO CEO & Investor Conference
Jan 10, 2022 07:30AM Soligenix Corporate Update Letter - Key Highlights and Upcoming Catalysts
Jan 6, 2022 07:30AM Soligenix to Present at Upcoming Investor Conferences
Jan 4, 2022 07:31AM Soligenix, Inc. (SNGX) Announces Dusquetide Demonstrates Positive Anti-tumor Efficacy in Multiple Nonclinical Animal Studies
View More Recent Stories View Older Stories